Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure (NCT01680783), a randomized na study. The primary outcome is Need for Endotracheal Intubation.

2. Clinical Question

3. Trial Design

The registry record describes a randomized, parallel-group trial with no masking. It lists enrollment of 83 and marks the study as completed. The sponsor is the University of Chicago. The record lists a start of 2012-09 and primary completion in 2016-05. The phase is recorded as NA.

The comparison was between usual care, described as continued noninvasive ventilation via facemask, and a helmet strategy for patients requiring facemask ventilation for more than 8 hours. In the helmet group, those patients were to switch to noninvasive ventilation using a helmet instead of the facemask. This description establishes the treatment contrast, but the registry record does not report details such as the randomization sequence, concealment of allocation, or how adherence and crossover were handled.

The primary endpoint was the number of participants requiring endotracheal intubation after application of the helmet device, measured over 6 weeks. The listed secondary outcomes include hospital length of stay, functional status after discharge, ventilator-free days, hospital mortality, and intensive care unit length of stay. The functional-status timeframe is described as measurement at 1, 6, and 12 months after hospital discharge, spanning up to 80 weeks depending on length of hospitalization. Hospital mortality has a 90-day timeframe.

The registry record does not report the trial’s original sample-size justification or its planned statistical analysis. It also does not report participant flow, the number of sites, or details of the enrolled population beyond the broad conditions listed. These omissions limit how fully the design and applicability of the results can be assessed.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Need for Endotracheal Intubation, measured over 6 weeks.

The primary endpoint is the count of participants requiring endotracheal intubation after application of the helmet device, assessed over 6 weeks. Intubation is an observable clinical event, and counting participants with that event provides a binary outcome: each participant is counted as having or not having the event within the stated timeframe. The registry describes the outcome in terms of participants, rather than an average measurement such as length of stay.

This endpoint is used to compare the frequency of escalation to invasive ventilation between the randomized groups. The posted counts are 24 of 39 participants in usual care and 8 of 44 in the helmet group. The posted risk difference, expressed as helmet minus usual care, is -0.434, with an interval from -0.624 to -0.243 and an unadjusted p < 0.001. These summaries describe the observed group contrast; they do not show whether every participant had complete follow-up or how the endpoint was adjudicated.

The record does not report a more detailed operational definition of intubation, the handling of events occurring after the 6-week period, or the rules used for participants with missing outcome information. Those details would help clarify how consistently the endpoint was measured and analyzed.

7. Results Posted in the Registry

• Non Invasive Ventilation Via Helmet: 18.2% (8/44) versus 61.5% (24/39) on control; risk difference -43.4 percentage points (95% CI -62.4 to -24.3), risk ratio 0.30 (0.15–0.58); unadjusted two-proportion z-test p = <0.001.

8. Secondary Efficacy Endpoints

The registry also posts results for secondary outcomes. For each outcome below, the endpoint type, the test applied to the posted summary statistics, the result and its interpretation are given in turn. Secondary endpoints are usually not adjusted for multiple testing, so they support rather than confirm the primary finding.

Number of Participants Functional Status After Discharge

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Non Invasive Ventilation Via Helmet: 50.0% (22/44) versus 15.4% (6/39) on control; risk difference 34.6 percentage points (95% CI 16.0 to 53.2), risk ratio 3.25 (1.47–7.18); unadjusted two-proportion z-test p = <0.001.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically higher for Non Invasive Ventilation Via Helmet than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

Hospital Mortality

• Endpoint type: Binary: the number of participants with the event, compared as proportions.
• Test: Unadjusted two-proportion z-test, with a Wald 95% confidence interval for the risk difference.
• Result:
  • Non Invasive Ventilation Via Helmet: 27.3% (12/44) versus 48.7% (19/39) on control; risk difference -21.4 percentage points (95% CI -41.9 to -1.0), risk ratio 0.56 (0.31–1.00); unadjusted two-proportion z-test p = 0.044.
• Interpretation:
  • The 95% confidence interval excludes no difference, so the proportion with the event is statistically lower for Non Invasive Ventilation Via Helmet than for the control. This is an unadjusted, secondary comparison, so it is suggestive rather than confirmatory.

The listed secondary outcomes cover functional status after discharge, hospital mortality, ventilator-free days, hospital length of stay, and intensive care unit length of stay. Detailed posted comparisons are available for functional status and hospital mortality. Results for ventilator-free days and the two length-of-stay outcomes are not reported in the registry record. The functional-status timeframe includes assessments at 1, 6, and 12 months after discharge and may span up to 80 weeks depending on hospitalization length; hospital mortality is reported for 90 days.

Across the two secondary outcomes with posted comparisons, the numerical directions are not identical: the functional-status count is higher in the helmet group, while the hospital-mortality count is lower in that group. These outcomes are not interchangeable with the primary endpoint. Intubation within 6 weeks is an event-specific measure, whereas functional status and mortality reflect different outcome domains and timeframes. Their relation to the primary result is therefore complementary rather than a direct repetition of it.

The registry record does not report the detailed definition of the functional-status outcome, nor does it describe how repeated assessment times were handled in the analysis. It also does not give an analysis method for the secondary outcomes. The posted contrasts are unadjusted, and the registry record lists no reported analyses for these outcomes.

In general, secondary outcomes can help describe a broader pattern, but each additional comparison creates another opportunity for an apparently notable result by chance. Without a reported prespecified hierarchy or multiplicity adjustment, unadjusted secondary p-values carry less confirmatory weight than a clearly prespecified primary analysis. The record does not report whether the secondary outcomes were prioritized in advance or how their results were intended to be interpreted together. Missing detailed results for some listed outcomes further limits assessment of the overall pattern.

Secondary outcomes registered for this trial, for reference (only those above were recalculated):

• Hospital Length of Stay
• Number of Participants Functional Status After Discharge
• Ventilator-free Days
• Hospital Mortality
• Intensive Care Unit Length of Stay

9. Statistical Interpretation

10. Statistical Methods Explained

The posted primary outcome is binary at the participant level: a participant either required endotracheal intubation within the stated 6-week timeframe or did not. For such an outcome, counts and proportions describe how often the event occurred in each arm. The counts are 24 of 39 in usual care and 8 of 44 in the helmet group. The displayed proportions are 0.615 and 0.182, respectively. These arm-specific summaries provide the basis for the reported contrasts.

What does the risk difference describe?

The risk difference subtracts the event proportion in one group from the event proportion in the other. The posted contrast is defined as helmet minus usual care, and its estimate is -0.434. A negative value therefore indicates that the observed event proportion was lower in the helmet group for this endpoint. The associated interval runs from -0.624 to -0.243. The interval is expressed on the risk-difference scale, so its endpoints describe plausible values for that same type of contrast under the interval procedure used. The confidence level and the method used to construct the interval are not reported in the registry record.

How do risk ratios and odds ratios differ?

A risk ratio compares the event proportion in one arm with the event proportion in the other. The posted risk ratio is 0.295, with an interval from 0.151 to 0.580. An odds ratio instead compares the odds of the event between arms; odds are not the same quantity as probabilities or proportions. The posted odds ratio is 0.139, with an interval from 0.051 to 0.378. These measures can look numerically different because they use different scales. They are not independent confirmations: both summarize the same event counts and group comparison.

In general, the risk difference is often straightforward to read as an absolute contrast in event proportions, while ratios describe relative contrasts. Which measure is most useful depends on the question and context. None of these measures alone addresses whether the observed difference is clinically important, whether the outcome was measured without bias, or whether the result applies outside the population studied.

What does the p-value add?

The unadjusted p-value for the primary comparison is p < 0.001. In general, a p-value measures how incompatible the observed data are with a specified null hypothesis under a particular statistical procedure. A small p-value is not the probability that the null hypothesis is true, and it does not measure the size or importance of an effect. The registry record does not name the test or report the exact analysis procedure, so the p-value should be treated as a posted unadjusted summary rather than as a fully documented analysis.

The record lists randomized allocation, but does not report whether the comparison followed an intention-to-treat approach, how participants with missing outcomes were handled, or whether any covariates were used. It also does not provide a named statistical analysis plan. These details matter because analysis choices can affect estimates, uncertainty, and the population to which the result refers.

For the posted binary outcomes, the figures are based on participant counts rather than event rates per unit of follow-up time. The record does not report time-to-event analyses for the primary endpoint. In general, a time-to-event method would account for event timing and censoring, whereas a simple participant count records whether an event occurred during a specified interval. The registry’s primary result should therefore be read as a comparison of participants with the event over the stated timeframe, not as an analysis of time until intubation.

The secondary comparisons also use binary counts in the posted results. Their unadjusted p-values describe each comparison separately. When multiple outcomes are examined, the chance of at least one apparently unusual result can increase if no adjustment or prespecified hierarchy is used. The record does not report a multiplicity strategy, so the secondary p-values should not be treated as if they were protected by a documented overall testing plan.

General statistical interpretation also distinguishes estimation from testing. An effect estimate gives the direction and scale of the observed contrast, while an interval conveys uncertainty around that estimate under a specified procedure. A p-value addresses compatibility with a null hypothesis under a test. These quantities answer related but different questions. Here, the confidence level, interval method, and test method are not reported in the registry record, which limits reconstruction of the analysis.

11. Confidence Intervals and Precision

The primary risk-difference estimate is -0.434, with an interval from -0.624 to -0.243. Both endpoints are below zero, consistent with a lower observed event proportion in the helmet group under the stated contrast direction. The interval also spans a range of possible effect magnitudes, rather than identifying one exact value. The confidence level and interval-construction method are not reported in the registry record, so the interval should not be assigned a confidence percentage that is absent from the record.

In general, a confidence interval communicates the uncertainty associated with an estimate under a statistical procedure. It is not a guarantee that the true effect lies within its endpoints, and it is not a measure of the probability that a treatment effect is clinically meaningful. A narrower interval generally indicates greater precision than a wider interval on the same scale, but precision does not eliminate risks of bias or limitations in applicability.

The alternative primary summaries also have intervals: the risk ratio is 0.295, with an interval from 0.151 to 0.580, and the odds ratio is 0.139, with an interval from 0.051 to 0.378. These intervals remain on their respective ratio scales and should not be read as risk-difference values. The registry record does not report the interval methods or confidence level for these measures either.

For hospital mortality, the posted risk difference is -0.214, with an interval from -0.419 to -0.010. Its upper endpoint is close to zero, so the range includes values near no difference as well as larger negative contrasts. The secondary result is unadjusted, and the registry does not report a multiplicity procedure. The interval and p-value should therefore be interpreted alongside the broader uncertainty about secondary analyses, rather than in isolation.

In general, precision depends on factors such as the amount of information in the data and the variability of the outcome. The registry enrollment is 83, and the reported arm counts are 39 and 44 for the primary endpoint. The record does not report a precision target or the original design assumptions, so it is not possible to judge the observed intervals against a planned target from the registry information alone.

12. Planning a Similar Trial: Sample Size

This is a planning illustration, not a re-evaluation of the original trial. It asks: if a new study wanted to detect a difference like the one observed, or a smaller one, how large would it need to be? It is deliberately not “observed power” of the finished trial, which is not a meaningful quantity.

The planning figures describe participants per arm, not the total number across both arms and not total events. The assumptions listed for these illustrations are a two-sided significance level of 0.05, equal allocation between the two arms, and a normal approximation. Each row uses a stated fraction of the observed effect: 100%, 75%, or 50%. These are planning assumptions for illustrations based on the observed contrast; the registry record does not report the original trial’s sample-size assumptions or justification.

The 80% power column gives the estimated number of participants per arm for a hypothetical study planned to have an 80% chance of detecting the specified effect, under those assumptions. The 90% power column gives the corresponding number per arm for a hypothetical study planned for a 90% chance. In general, higher target power requires more information, and a smaller effect is harder to distinguish from random variation than a larger effect. Accordingly, the planning figures increase as the assumed effect fraction becomes smaller.

These values are not a retrospective measure of how likely this completed trial was to find a result, and they do not describe its observed power. They are illustrations of how design size changes when the target effect and desired power change, while holding the stated planning assumptions fixed. Because the effect fractions are anchored to the observed effect, the illustrations should not be treated as independent evidence that the observed effect is the effect a future study should expect.

The figures also do not establish what enrollment would be needed under different allocation, significance, outcome, or analysis assumptions. The record does not report those alternative design choices, nor does it report whether the original trial used the same assumptions as the illustrations.

13. How the Sample Size Is Derived

Power is the probability that a study of a given size rejects the null hypothesis when a specific true effect exists. It depends on four things: the effect to detect, the variability of the outcome, the significance level (here a two-sided α of 0.05, so z_1−α/2 = 1.960) and the desired power (z_1−β = 0.842 for 80% and 1.282 for 90%).

Formula

n is the number of participants in each arm, p₀ and p₁ are the control and treatment proportions, and p̄ is their average.

Worked calculation for this trial

1. Control proportion p₀ = 0.615; treatment proportion p₁ = 0.182; average p̄ = 0.399.
2. First term: z_1−α/2 × √[2p̄(1−p̄)] = 1.96 × 0.6924 = 1.3571.
3. Second term: z_1−β × √[p₀(1−p₀) + p₁(1−p₁)] = 0.842 × 0.6208 = 0.5225.
4. n = (1.3571 + 0.5225)² / (-0.4336)² = 18.8, rounded up to 19 participants per arm for 80% power.

The smaller-effect rows in the table above repeat the same calculation with the effect multiplied by 0.75 and 0.5 (for ratios, applied to the logarithm of the ratio).

R code

alpha <- 0.05
z_a   <- qnorm(1 - alpha / 2)          # two-sided
p0 <- 0.615384615384615                          # control proportion
p1 <- 0.181818181818182                          # treatment proportion
n_per_arm <- function(power, frac = 1) {
  q1 <- p0 + (p1 - p0) * frac               # smaller effect = fraction of the observed difference
  pbar <- (p0 + q1) / 2
  z_b <- qnorm(power)
  ceiling(round((z_a * sqrt(2 * pbar * (1 - pbar)) + z_b * sqrt(p0 * (1 - p0) + q1 * (1 - q1)))^2 / (q1 - p0)^2, 6))
}
for (f in c(1, 0.75, 0.5))
  cat(sprintf("%3.0f%% of observed effect: n per arm = %s (80%% power), %s (90%% power)\n", 100 * f,
              format(n_per_arm(0.80, f), big.mark = ","), format(n_per_arm(0.90, f), big.mark = ",")))

# Check against R's built-in function (unrounded n per arm)
cat("power.prop.test:", round(power.prop.test(p1 = p0, p2 = p1, power = 0.80)$n, 1), "\n")

# Simulation: how often does the z-test reject at the 80%-power sample size?
set.seed(1680783)
n    <- n_per_arm(0.80)
reps <- 20000
x0 <- rbinom(reps, n, p0); x1 <- rbinom(reps, n, p1)
ph <- (x0 + x1) / (2 * n)
z  <- ((x1 - x0) / n) / sqrt(ph * (1 - ph) * 2 / n)
cat(sprintf("Simulated power at n = %s per arm: %.3f (%d replicates)\n", format(n, big.mark = ","), mean(abs(z) > z_a, na.rm = TRUE), reps))

Output from running the code

100% of observed effect: n per arm = 19 (80% power), 25 (90% power)
 75% of observed effect: n per arm = 36 (80% power), 48 (90% power)
 50% of observed effect: n per arm = 83 (80% power), 110 (90% power)
power.prop.test: 18.8 
Simulated power at n = 19 per arm: 0.828 (20000 replicates)

The simulation draws many pairs of event counts at the planned sample size and counts how often the two-proportion z-test rejects the null. It should land close to the target power; at very small required sample sizes it can fall below it, because the normal approximation is rough there.

14. Multiplicity, Missing Data and Analysis Populations

The registry record lists multiple outcomes, including one primary endpoint and several secondary outcomes. It does not report a multiplicity adjustment, a testing hierarchy, or a strategy for controlling the chance of false-positive findings across outcomes. General statistical practice treats this as important context: interpreting many unadjusted tests as though each were the sole planned test can overstate the strength of evidence. The posted secondary p-values should therefore be read as outcome-specific summaries rather than as results protected by a documented family-wise analysis plan.

The record does not report missing-data counts, exclusions from analysis, or methods for handling unavailable outcomes. Although the posted comparisons have arm denominators of 39 and 44, those denominators alone do not establish whether every randomized participant had complete follow-up or whether other participants were excluded. The analysis population is not named; in particular, the registry record does not state whether the primary comparison used an intention-to-treat, per-protocol, or other population.

Details of randomization, allocation concealment, and treatment adherence are not reported. The study is marked as having no masking, but the record does not explain outcome assessment procedures or whether endpoint adjudication was independent of treatment assignment. These omissions are relevant when considering the potential for deviations from assigned treatment or differences in outcome ascertainment.

The registry record reports no named analyses, and it does not describe the statistical plan, the test used for the posted p-values, or the methods used to construct intervals. The absence of those details does not change the arithmetic meaning of the posted counts and contrasts, but it makes it harder to judge whether analyses followed a prespecified plan and how uncertainty was quantified.

15. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

The adverse-event counts list zero serious adverse events among 39 participants in usual care and zero among 44 participants in the helmet group. The counts for other adverse events are also zero among 39 and zero among 44, respectively. No serious-event terms are listed. These figures describe what is recorded in the registry record; they do not establish that no events occurred beyond the recorded reporting period or that all event types were captured.

The record does not provide definitions of serious or other adverse events, ascertainment methods, reporting windows, or information about event severity and relatedness. The listed death counts are 22 in usual care and 12 in the helmet group, but death counts are not interchangeable with adverse-event counts and should be interpreted using the separately reported hospital-mortality outcome and its timeframe. These counts alone do not establish why deaths occurred or whether they were caused by an intervention.

Zero recorded events in these summaries should not be read as proof of equal safety. The trial’s enrollment and the limited detail about adverse-event collection constrain what can be inferred from the absence of recorded events.

16. What the Result Does, and Does Not, Mean

The primary data describe fewer participants requiring endotracheal intubation in the helmet group than in usual care during the 6-week timeframe. The posted risk difference is negative for helmet minus usual care, and its interval remains below zero. The unadjusted p-value is p < 0.001. These are statistical descriptions of the trial’s recorded groups and endpoint, not a general guarantee about outcomes in other settings.

The result does not establish that the intervention is beneficial or harmful in clinical practice, and it is not medical advice. The registry record does not provide enough information to judge all aspects of clinical importance, endpoint ascertainment, participant eligibility, or treatment adherence. Nor does the primary endpoint answer every question about mortality, functional status, or duration of hospitalization.

The secondary findings cover different outcomes and follow-up periods. Their numerical directions should not be collapsed into one overall treatment conclusion, especially because they are unadjusted and the record does not report a multiplicity plan. Several listed secondary outcomes lack detailed posted results. The absence of those results prevents a complete review of the outcome pattern.

General interpretation of randomized comparisons also depends on how randomization was carried out, whether assigned treatment was followed, how missing observations were handled, and whether analysis choices were prespecified. Those details are not reported in the registry record. The finding should therefore be understood as a comparison of the posted counts and estimates, with the stated uncertainty and the limits of registry reporting in view.

17. Why This Trial Matters Statistically

This trial is statistically useful as an example of how a binary clinical endpoint can be reported in several complementary ways. The participant counts show the observed events in each randomized arm, while the risk difference expresses the absolute contrast and the risk ratio and odds ratio express relative contrasts on different scales. Reading the estimates alongside their intervals helps distinguish effect magnitude from uncertainty.

It also illustrates that statistical evidence and clinical interpretation are separate tasks. The primary p-value is small, and the interval for the risk difference is below zero, but these registry entries do not by themselves determine clinical importance or applicability. That assessment also depends on the endpoint definition, follow-up, population, study conduct, and completeness of the analysis description.

The registry record makes the lack of masking explicit but leaves important analysis details undocumented. It does not describe missing-data procedures, analysis populations, interval methods, or a plan for handling multiple outcomes. The secondary results demonstrate why these omissions matter: a collection of unadjusted findings across distinct endpoints and timeframes should not be treated as a single confirmatory conclusion.

Finally, planning illustrations based on an observed effect can show how target effect size and desired power influence hypothetical enrollment. They do not reveal the assumptions used to design the completed trial and do not measure its observed power. Keeping that distinction clear is important when translating a result into a future study plan.

18. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The registry gives limited detail about who was eligible and who was actually enrolled. It lists acute respiratory distress syndrome, shock, ventilatory failure, and cardiogenic pulmonary edema, but does not report the inclusion and exclusion criteria or describe the distribution of participants across these conditions. Applicability to a particular clinical subgroup therefore cannot be assessed from the registry record alone.

The trial is recorded as randomized and unmasked, but the record does not describe the randomization procedure, concealment, adherence, crossover, or co-interventions. It also does not report the endpoint adjudication process or how missing outcome data were handled. These gaps constrain assessment of potential bias and of the analysis population.

Enrollment is listed as 83, and the primary endpoint is measured over 6 weeks. The record does not report the original sample-size justification, a prespecified statistical analysis plan, or the test and interval methods used. Although planning illustrations are listed, they are based on the observed effect and are not the trial’s reported design assumptions.

Only two secondary outcomes have detailed posted comparisons in the registry record, while other listed secondary outcomes lack corresponding results. Functional status is described at multiple follow-up times, but the registry record does not report the outcome definition or how those assessments were analyzed together. The safety record gives event counts but not definitions, reporting procedures, or relatedness. These limitations make the posted results informative as recorded contrasts but leave important questions about conduct, measurement, and completeness unresolved.

19. Related Tutorials

20. Related Statistical Calculators

21. Sources

• ClinicalTrials.gov: Non-Invasive Ventilation Via a Helmet Device for Patients Respiratory Failure — NCT01680783.
• Registry record last updated 2020-07-14; status last verified 2020-07.
• Results first posted 2017-07-02.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

22. Record Summary

The registry record describes NCT01680783 as a completed randomized, parallel-group trial with no masking, sponsored by the University of Chicago. Enrollment is listed as 83. The comparison is usual care with continued noninvasive ventilation via facemask versus switching to noninvasive ventilation via a helmet device for patients requiring facemask ventilation for more than 8 hours.

The primary outcome is the number of participants requiring endotracheal intubation within 6 weeks. The posted counts are 24 of 39 in usual care and 8 of 44 in the helmet group, with a risk difference of -0.434 and unadjusted p < 0.001. Detailed secondary comparisons are posted for functional status after discharge and hospital mortality. Other listed secondary outcomes do not have detailed results reported in the registry record.

The record does not report the original sample-size rationale, statistical analysis plan, missing-data handling, analysis populations, or multiplicity strategy. These omissions limit full assessment of the methods and the broader interpretation of the posted comparisons.